Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCELERON PHARMA INCXLRN · Entity 15780 | EVP & Chief Medical Officer | April 03, 2018 | April 04, 2018 |
| LUMOS PHARMA, INC.(NLNK) · Entity 85102 | Director | July 31, 2019 | August 02, 2019 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | June 21, 2023 | June 23, 2023 |
| Pulmatrix, Inc.PULM · Entity 8249 | Director | May 16, 2019 | May 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCELERON PHARMA INC
Report date April 03, 2018 · Filed April 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,767 |
Ending reported balance
After 2018-04-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-03 · Sale · Disposed 3,700 · Balance 69,667 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Row 2 · 2018-04-03 · Sale · Disposed 900 · Balance 68,767 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Irrevocable Trust | 8,500 |
Reported balance
Holding disclosure · report date 2018-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
LUMOS PHARMA, INC.
Report date July 31, 2019 · Filed August 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2028-04-29 | Direct | 0 |
Reported balance
After 2019-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-31 · Disposition to issuer · Disposed 63,447 · Balance 0 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2026-07-31 | Direct | 13,218 |
Reported balance
After 2019-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-31 · Grant · Acquired 13,218 · Balance 13,218 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2026-07-31 | Direct | 18,506 |
Reported balance
After 2019-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-31 · Grant · Acquired 18,506 · Balance 18,506 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F3: The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2028-05-22 | Direct | 0 |
Reported balance
After 2019-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-31 · Disposition to issuer · Disposed 27,777 · Balance 0 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F4: The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2026-07-31 | Direct | 13,889 |
Reported balance
After 2019-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-31 · Grant · Acquired 13,889 · Balance 13,889 F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
F2: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
F3: The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.
F4: The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date.
PALVELLA THERAPEUTICS, INC.
Report date June 21, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2033-06-21 | Direct | 40,000 |
Reported balance
After 2023-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-21 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date.
Pulmatrix, Inc.
Report date May 16, 2019 · Filed May 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-05-16 | Direct | 15,000 |
Reported balance
After 2019-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-16 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 11, 2024
Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 144,290 |
Reported balance
After 2024-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 34,157 · Balance 144,290 F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. F2: Includes 1,394 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 72,261 |
Reported balance
After 2024-06-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-06-11 · Disposition to issuer · Disposed 72,029 · Balance 72,261 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-06-11 · Other · Disposed 72,261 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 82,265 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-11 · Disposition to issuer · Disposed 82,000 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-11 · Disposition to issuer · Disposed 65,900 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.92 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-06-11 · Disposition to issuer · Disposed 69,100 · Balance 0 F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred.
F2: Includes 1,394 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2024.
F3: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding.
F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2019 Filed Aug 2, 2019 18:39 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 63,447 | Not disclosed Strike: $4.56 | Not disclosed |
DisclosureSEC source: 0001126234-19-000106 · wf-form4_156478558165297.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,447 shares Expires 2028-04-29 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. Read SEC document |
| May 16, 2019 Filed May 20, 2019 16:13 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000899243-19-014141 · doc4.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| May 10, 2019 Filed May 14, 2019 17:33 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001126234-19-000059 · wf-form4_155786961881847.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-09 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan, as amended (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:46 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001562180-19-000580 · primarydocument.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| October 24, 2018 Filed Oct 25, 2018 17:21 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001562180-18-004281 · primarydocument.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-10-24 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on October 24, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 18:00 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0000899243-18-015297 · doc4.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: One-fourth (1/4) of the option vested on June 5, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow June 5, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| May 23, 2018 Filed May 25, 2018 18:00 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 27,777 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001126234-18-000099 · wf-form4_152728562008093.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,777 Underlying: Common Stock · 27,777 shares Expires 2028-05-22 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 16:39 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 900 | $39.04 | $35,136.00 |
DisclosureSEC source: 0001179110-18-005397 · edgar.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,767 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 16:39 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 3,700 | $38.28 | $141,636.00 |
DisclosureSEC source: 0001179110-18-005397 · edgar.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,667 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:07 UTC | Pulmatrix, Inc. PULM · Entity 8249 | PurchaseSeries B Warrant (right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-009608 · doc4.xml · derivative · entry 3 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-04-03 F1 · price: The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:07 UTC | Pulmatrix, Inc. PULM · Entity 8249 | PurchaseSeries A Warrant (right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0000899243-18-009608 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-10-03 F1 · price: The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:07 UTC | Pulmatrix, Inc. PULM · Entity 8249 | PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-009608 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 19:02 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 2,033 | $43.33 | $88,089.89 |
DisclosureSEC source: 0001179110-18-000545 · edgar.xml · nonDerivative · entry 3 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,367 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.50 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 19:02 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 2,300 | $42.40 | $97,520.00 |
DisclosureSEC source: 0001179110-18-000545 · edgar.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,400 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.86 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 19:02 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 300 | $40.86 | $12,258.00 |
DisclosureSEC source: 0001179110-18-000545 · edgar.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,700 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.85 to $40.87 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 17:02 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 150 | $39.91 | $5,986.50 |
DisclosureSEC source: 0001179110-17-012288 · edgar.xml · nonDerivative · entry 3 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.87 to $39.93 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 17:02 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,600 | $39.24 | $62,784.00 |
DisclosureSEC source: 0001179110-17-012288 · edgar.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,150 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 to $39.75 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 17:02 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 16,650 | $38.32 | $638,028.00 |
DisclosureSEC source: 0001179110-17-012288 · edgar.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,750 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.81 to $38.80 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:55 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001179110-17-010224 · edgar.xml · derivative · entry 4 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2022-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:55 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 16,000 | $32.00 | $512,000.00 |
DisclosureSEC source: 0001179110-17-010224 · edgar.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,400 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:55 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 8,000 | $7.12 | $56,960.00 |
DisclosureSEC source: 0001179110-17-010224 · edgar.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 18:51 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008412 · doc4.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on March 20, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 18:15 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 47,300 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001179110-17-004589 · edgar.xml · derivative · entry 3 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,300 Underlying: Common Stock · 47,300 shares Expires 2027-03-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 18:15 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 7,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004589 · edgar.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,400 Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:12 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,600 | $27.62 | $44,192.00 |
DisclosureSEC source: 0001179110-17-000681 · edgar.xml · nonDerivative · entry 2 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,500 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.45 to $27.79, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:12 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 400 | $26.81 | $10,724.00 |
DisclosureSEC source: 0001179110-17-000681 · edgar.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,100 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.42 to $27.32, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 11:05 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000899243-16-030535 · doc4.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2026-09-29 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on September 29, 2017 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow September 29, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.